Media

  • Home
  • About Us
  • Products + Pipeline
    • About Cenobamate
  • Healthcare Professionals
  • About Epilepsy
  • Careers
  • Media
    • Press Release
    • Events
  • Contact
  • News + Press Releases
  • Events

Angelini Pharma acquires Arvelle Therapeutics to create a leading European innovator in Central Nervous System (CNS) and Mental Health Disorder treatments

Angelini Pharma and Arvelle Therapeutics have today agreed on a definitive merger agreement valuing Arvelle Therapeutics at up to $960 million…

Read more January 4, 2021

Arvelle Announces Partnership with Durbin Across Europe

Zug, Switzerland, 17 August 2020 – Arvelle Therapeutics, an emerging biopharmaceutical company focused on bringing innovative treatments to…

Read more August 17, 2020

Cenobamate Designated Promising Innovative Medicine (PIM) by the UK’s MHRA for Treatment of Drug-Resistant Focal-Onset Seizures in Adults

PIM designation is an early indication that cenobamate is a promising candidate for the MHRA’s Early Access to Medicine Scheme Milestone further…

Read more August 11, 2020

Arvelle to Present at Jefferies Virtual 2020 Healthcare Conference

Zug, Switzerland, 1 June 2020 – Arvelle Therapeutics, an emerging biopharmaceutical company focused on bringing innovative treatments to…

Read more June 1, 2020

Arvelle Announces Closing of Final Tranche of Series A Financing Round

Brings the total financing to $207.8m Triggered by successful filing and validation of the MAA for cenobamate Zug, Switzerland, 26 May 2020 –…

Read more May 26, 2020

Results of a Randomised Study Showing that Adjunctive Cenobamate Significantly Improved Seizure control in Adults with Uncontrolled Focal Seizures Published in Neurology 1

28% of patients receiving cenobamate achieved seizure-freedom (zero seizures) during the study’s maintenance phase, versus 9% receiving placebo1…

Read more May 21, 2020

SK Life Science, Inc. Announces US Availability of XCOPRI® (cenobamate tablets) for the Treatment of Partial (Focal) Onset Seizures in Adults with Epilepsy

Arvelle Therapeutics has exclusive rights to develop and commercialize cenobamate in Europe Zug, Switzerland, 12 May 2020 – Arvelle…

Read more May 12, 2020

Arvelle Announces European Medicines Agency Acceptance of the Marketing Authorization Application (MAA) for Cenobamate

The MAA seeks authorisation for the adjunctive treatment of focal-onset seizures in adult patients with epilepsy Zug, Switzerland, 26 March 2020…

Read more March 26, 2020

Appointment of Dr Otto Schwarz as Independent Director and Chairman of the Board

Zug, Switzerland, December 4, 2019 – Arvelle Therapeutics GmbH (“Arvelle”), an emerging biopharmaceutical company focused on bringing…

Read more December 4, 2019

SK Life Science, Inc. Receives US FDA Approval for cenobamate tablets for the Treatment of Partial-Onset Seizures in Adults with Epilepsy

Approval based on pivotal trials that assessed the efficacy and safety of cenobamate Arvelle Therapeutics has exclusive rights to develop and…

Read more November 25, 2019
Next
+41 44 5672940 info@arvelletx.com

Arvelle Therapeutics
International GmbH
Zählerweg 6,
6301 Zug, Switzerland

LinkedIn LinkedIn Twitter Twitter
  • Home
  • Privacy Policy